Search

Your search keyword '"Wu, Y.-L."' showing total 1,769 results
Start Over Author "Wu, Y.-L."
1,769 results on '"Wu, Y.-L."'

203. Prediction of the planet yield of the MaxProtoPlanetS high-contrast survey for H-alpha protoplanets with MagAO-X based on first light contrasts

Author

Close, L.M., Males, J., Long, J.D., Gorkom, K. van, Hedglen, A.D., Kautz, M., Lumbres, J., Haffert, S.Y., Follette, K., Wagner, K., Miller, K.L., Apai, D., Wu, Y.-L., Guyon, O., Schatz, L., Rodack, A., Doelman, D.S., Snik, F., Knight, J.M., Morzinski, K., Gasho, V., Keller, C.U., Pearce, L., Weinberger, A., Perez, L., Doyon, R., Schreiber, L., Schmidt, D., Vernet, E., Schreiber, L., Schmidt, D., and Vernet, E.

Subjects
Physics, Yield (engineering), 02 engineering and technology, Astrophysics, First light, 021001 nanoscience & nanotechnology, 01 natural sciences, Exoplanet, Accretion (astrophysics), 010309 optics, Stars, Planet, 0103 physical sciences, H-alpha, 0210 nano-technology, Protoplanet
Abstract

Our past GAPplanetS survey over the last 5 years with the MagAO visible AO system discovered the first examples of accreting protoplanets (by direct observation of H-alpha emission). Examples include LkCa15 b (Sallum et al. 2015) and PDS70 b (Wagner et al. 2018). In this paper we review the science performance of the newly (Dec. 2019) commissioned MagAO-X extreme AO system. In particular, we use the vAPP coronagraphic contrasts measured during MagAO-X first light. We use the Massive Accreting Gap (MAG) protoplanet model of Close 2020 to predict the H-alpha contrasts of 19 of the best transitional disk systems (ages 1-5 Myr) for the direct detection of H-alpha from accretion of hydrogen onto these protoplanets. The MAG protoplanet model applied to the observed first light MagAO-X contrasts predict a maximum yield of 46±7 planets from 19 stars (42 of these planets would be new discoveries). This suggests that there is a large, yet, unexplored reservoir of protoplanets that can be discovered with an extreme AO coronagraphic survey of 19 of the best transitional disk systems. Based on our first light contrasts we predict a healthy yield of protoplanets from our MaxProtoPlanetS survey of 19 transitional disks with MagAO-X.

Published
2020

204. Early noninvasive cardiac testing after emergency department evaluation for suspected acute coronary syndrome

Author

Kawatkar, A.A., Sharp, A.L., Baecker, A.S., Natsui, S., Redberg, R.F., Lee, M.-S., Ferencik, M., Wu, Y.-L., Shen, E., Zheng, C., Musigdilok, V.V., Gould, M.K., Goodacre, S., Thokala, P., and Sun, B.C.

Abstract

Importance Professional guidelines recommend noninvasive cardiac testing (NIT) within 72 hours of an emergency department (ED) evaluation for suspected acute coronary syndrome. However, there is inexact evidence that this strategy reduces the risk of future death or acute myocardial infarction (MI).\ud \ud \ud \ud Objective To evaluate the effectiveness of early NIT in reducing the risk of death or acute MI within 30 days.\ud \ud \ud \ud Design, Setting, and Participants This retrospective, multicenter cohort study within the Kaiser Permanente Southern California integrated health care delivery system compared the effectiveness of early noninvasive cardiac testing vs no testing in patients with chest pain and in whom acute MI was ruled out who presented to an ED from January 2015 to December 2017. Patients were followed up for up to 30 days after emergency department discharge.\ud \ud \ud \ud Exposures Noninvasive cardiac testing performed within 3 days of an ED evaluation for suspected acute coronary syndrome.\ud \ud \ud \ud Main Outcomes and Measures The primary outcome was composite risk of death or acute MI, within 30 days of an ED discharge.\ud \ud \ud \ud Results A total of 79 040 patients were evaluated in this study, of whom 57.7% were female. The mean (SD) age of the cohort was 57 (16) years, and 16 164 patients (21%) had completed early NIT. The absolute risk of death or MI within 30 days was low (

Published
2020

211. 32O First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Author

Chen, H-J., primary, Yang, J-J., additional, Zhou, J-Y., additional, Zhao, J., additional, Sun, Y-P., additional, Wen, Q., additional, Zhou, Q., additional, Zhang, Z., additional, Tu, H-Y., additional, Zhang, P., additional, Chen, X., additional, Chen, H-X., additional, Dang, Q., additional, Sun, M-H., additional, Li, Y., additional, and Wu, Y-L., additional

Published
2021
Full Text
View/download PDF

220. Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women

Author

Wong, Jason Y Y, Wong, Jason Y Y, Zhang, Han, Hsiung, Chao A, Shiraishi, Kouya, Yu, Kai, Matsuo, Keitaro, Wong, Maria Pik, Hong, Yun-Chul, Wang, Jiucun, Seow, Wei Jie, Wang, Zhaoming, Song, Minsun, Kim, Hee Nam, Chang, I-Shou, Chatterjee, Nilanjan, Hu, Wei, Wu, Chen, Mitsudomi, Tetsuya, Zheng, Wei, Kim, Jin Hee, Seow, Adeline, Caporaso, Neil E, Shin, Min-Ho, Chung, Lap Ping, An, She-Juan, Wang, Ping, Yang, Yang, Zheng, Hong, Yatabe, Yasushi, Zhang, Xu-Chao, Kim, Young Tae, Cai, Qiuyin, Yin, Zhihua, Kim, Young-Chul, Bassig, Bryan A, Chang, Jiang, Ho, James Chung Man, Ji, Bu-Tian, Daigo, Yataro, Ito, Hidemi, Momozawa, Yukihide, Ashikawa, Kyota, Kamatani, Yoichiro, Honda, Takayuki, Hosgood, H Dean, Sakamoto, Hiromi, Kunitoh, Hideo, Tsuta, Koji, Watanabe, Shun-Ichi, Kubo, Michiaki, Miyagi, Yohei, Nakayama, Haruhiko, Matsumoto, Shingo, Tsuboi, Masahiro, Goto, Koichi, Shi, Jianxin, Song, Lei, Hua, Xing, Takahashi, Atsushi, Goto, Akiteru, Minamiya, Yoshihiro, Shimizu, Kimihiro, Tanaka, Kazumi, Wei, Fusheng, Matsuda, Fumihiko, Su, Jian, Kim, Yeul Hong, Oh, In-Jae, Song, Fengju, Su, Wu-Chou, Chen, Yu-Min, Chang, Gee-Chen, Chen, Kuan-Yu, Huang, Ming-Shyan, Chien, Li-Hsin, Xiang, Yong-Bing, Park, Jae Yong, Kweon, Sun-Seog, Chen, Chien-Jen, Lee, Kyoung-Mu, Blechter, Batel, Li, Haixin, Gao, Yu-Tang, Qian, Biyun, Lu, Daru, Liu, Jianjun, Jeon, Hyo-Sung, Hsiao, Chin-Fu, Sung, Jae Sook, Tsai, Ying-Huang, Jung, Yoo Jin, Guo, Huan, Hu, Zhibin, Wang, Wen-Chang, Chung, Charles C, Burdett, Laurie, Yeager, Meredith, Hutchinson, Amy, Berndt, Sonja I, Wu, Wei, Pang, Herbert, Li, Yuqing, Choi, Jin Eun, Park, Kyong Hwa, Sung, Sook Whan, Liu, Li, Kang, C H, Zhu, Meng, Chen, Chung-Hsing, Yang, Tsung-Ying, Xu, Jun, Guan, Peng, Tan, Wen, Wang, Chih-Liang, Hsin, Michael, Sit, Ko-Yung, Ho, James, Chen, Ying, Choi, Yi Young, Hung, Jen-Yu, Kim, Jun Suk, Yoon, Ho Il, Lin, Chien-Chung, Park, In Kyu, Xu, Ping, Wang, Yuzhuo, He, Qincheng, Perng, Reury-Perng, Chen, Chih-Yi, Vermeulen, Roel, Wu, Junjie, Lim, Wei-Yen, Chen, Kun-Chieh, Li, Yao-Jen, Li, Jihua, Chen, Hongyan, Yu, Chong-Jen, Jin, Li, Chen, Tzu-Yu, Jiang, Shih-Sheng, Liu, Jie, Yamaji, Taiki, Hicks, Belynda, Wyatt, Kathleen, Li, Shengchao A, Dai, Juncheng, Ma, Hongxia, Jin, Guangfu, Song, Bao, Wang, Zhehai, Cheng, Sensen, Li, Xuelian, Ren, Yangwu, Cui, Ping, Iwasaki, Motoki, Shimazu, Taichi, Tsugane, Shoichiro, Zhu, Junjie, Yang, Kaiyun, Jiang, Gening, Fei, Ke, Wu, Guoping, Lin, Hsien-Chin, Chen, Hui-Ling, Fang, Yao-Huei, Tsai, Fang-Yu, Hsieh, Wan-Shan, Yu, Jinming, Stevens, Victoria L, Laird-Offringa, Ite A, Marconett, Crystal N, Rieswijk, Linda, Chao, Ann, Yang, Pan-Chyr, Shu, Xiao-Ou, Wu, Tangchun, Wu, Y L, Lin, Dongxin, Chen, Kexin, Zhou, Baosen, Huang, Yun-Chao, Kohno, Takashi, Shen, Hongbing, Chanock, Stephen J, Rothman, Nathaniel, Lan, Qing, Wong, Jason Y Y, Wong, Jason Y Y, Zhang, Han, Hsiung, Chao A, Shiraishi, Kouya, Yu, Kai, Matsuo, Keitaro, Wong, Maria Pik, Hong, Yun-Chul, Wang, Jiucun, Seow, Wei Jie, Wang, Zhaoming, Song, Minsun, Kim, Hee Nam, Chang, I-Shou, Chatterjee, Nilanjan, Hu, Wei, Wu, Chen, Mitsudomi, Tetsuya, Zheng, Wei, Kim, Jin Hee, Seow, Adeline, Caporaso, Neil E, Shin, Min-Ho, Chung, Lap Ping, An, She-Juan, Wang, Ping, Yang, Yang, Zheng, Hong, Yatabe, Yasushi, Zhang, Xu-Chao, Kim, Young Tae, Cai, Qiuyin, Yin, Zhihua, Kim, Young-Chul, Bassig, Bryan A, Chang, Jiang, Ho, James Chung Man, Ji, Bu-Tian, Daigo, Yataro, Ito, Hidemi, Momozawa, Yukihide, Ashikawa, Kyota, Kamatani, Yoichiro, Honda, Takayuki, Hosgood, H Dean, Sakamoto, Hiromi, Kunitoh, Hideo, Tsuta, Koji, Watanabe, Shun-Ichi, Kubo, Michiaki, Miyagi, Yohei, Nakayama, Haruhiko, Matsumoto, Shingo, Tsuboi, Masahiro, Goto, Koichi, Shi, Jianxin, Song, Lei, Hua, Xing, Takahashi, Atsushi, Goto, Akiteru, Minamiya, Yoshihiro, Shimizu, Kimihiro, Tanaka, Kazumi, Wei, Fusheng, Matsuda, Fumihiko, Su, Jian, Kim, Yeul Hong, Oh, In-Jae, Song, Fengju, Su, Wu-Chou, Chen, Yu-Min, Chang, Gee-Chen, Chen, Kuan-Yu, Huang, Ming-Shyan, Chien, Li-Hsin, Xiang, Yong-Bing, Park, Jae Yong, Kweon, Sun-Seog, Chen, Chien-Jen, Lee, Kyoung-Mu, Blechter, Batel, Li, Haixin, Gao, Yu-Tang, Qian, Biyun, Lu, Daru, Liu, Jianjun, Jeon, Hyo-Sung, Hsiao, Chin-Fu, Sung, Jae Sook, Tsai, Ying-Huang, Jung, Yoo Jin, Guo, Huan, Hu, Zhibin, Wang, Wen-Chang, Chung, Charles C, Burdett, Laurie, Yeager, Meredith, Hutchinson, Amy, Berndt, Sonja I, Wu, Wei, Pang, Herbert, Li, Yuqing, Choi, Jin Eun, Park, Kyong Hwa, Sung, Sook Whan, Liu, Li, Kang, C H, Zhu, Meng, Chen, Chung-Hsing, Yang, Tsung-Ying, Xu, Jun, Guan, Peng, Tan, Wen, Wang, Chih-Liang, Hsin, Michael, Sit, Ko-Yung, Ho, James, Chen, Ying, Choi, Yi Young, Hung, Jen-Yu, Kim, Jun Suk, Yoon, Ho Il, Lin, Chien-Chung, Park, In Kyu, Xu, Ping, Wang, Yuzhuo, He, Qincheng, Perng, Reury-Perng, Chen, Chih-Yi, Vermeulen, Roel, Wu, Junjie, Lim, Wei-Yen, Chen, Kun-Chieh, Li, Yao-Jen, Li, Jihua, Chen, Hongyan, Yu, Chong-Jen, Jin, Li, Chen, Tzu-Yu, Jiang, Shih-Sheng, Liu, Jie, Yamaji, Taiki, Hicks, Belynda, Wyatt, Kathleen, Li, Shengchao A, Dai, Juncheng, Ma, Hongxia, Jin, Guangfu, Song, Bao, Wang, Zhehai, Cheng, Sensen, Li, Xuelian, Ren, Yangwu, Cui, Ping, Iwasaki, Motoki, Shimazu, Taichi, Tsugane, Shoichiro, Zhu, Junjie, Yang, Kaiyun, Jiang, Gening, Fei, Ke, Wu, Guoping, Lin, Hsien-Chin, Chen, Hui-Ling, Fang, Yao-Huei, Tsai, Fang-Yu, Hsieh, Wan-Shan, Yu, Jinming, Stevens, Victoria L, Laird-Offringa, Ite A, Marconett, Crystal N, Rieswijk, Linda, Chao, Ann, Yang, Pan-Chyr, Shu, Xiao-Ou, Wu, Tangchun, Wu, Y L, Lin, Dongxin, Chen, Kexin, Zhou, Baosen, Huang, Yun-Chao, Kohno, Takashi, Shen, Hongbing, Chanock, Stephen J, Rothman, Nathaniel, and Lan, Qing

Abstract

We investigated whether genetic susceptibility to tuberculosis (TB) influences lung adenocarcinoma development among never-smokers using TB genome-wide association study (GWAS) results within the Female Lung Cancer Consortium in Asia. Pathway analysis with the adaptive rank truncated product method was used to assess the association between a TB-related gene-set and lung adenocarcinoma using GWAS data from 5512 lung adenocarcinoma cases and 6277 controls. The gene-set consisted of 31 genes containing known/suggestive associations with genetic variants from previous TB-GWAS. Subsequently, we followed-up with Mendelian Randomization to evaluate the association between TB and lung adenocarcinoma using three genome-wide significant variants from previous TB-GWAS in East Asians. The TB-related gene-set was associated with lung adenocarcinoma (p = 0.016). Additionally, the Mendelian Randomization showed an association between TB and lung adenocarcinoma (OR = 1.31, 95% CI: 1.03, 1.66, p = 0.027). Our findings support TB as a causal risk factor for lung cancer development among never-smoking Asian women.

Published
2020

221. POTENTIAL MECHANISMS OF RESISTANCE IDENTIFIED THROUGH ANALYSIS OF MULTIPLE BIOMARKERS IN IMMUNE HOT NON-RESPONDERS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH TISLELIZUMAB

Author

Desai, J, Zhou, Q, Deva, S, Zhao, J, Wang, J, Tan, W, Ma, X, Zhang, Y, Shen, Z, Wu, X, Leaw, S, Zhang, J, Wu, Y-L, Desai, J, Zhou, Q, Deva, S, Zhao, J, Wang, J, Tan, W, Ma, X, Zhang, Y, Shen, Z, Wu, X, Leaw, S, Zhang, J, and Wu, Y-L

Abstract

Background Tislelizumab, an anti-PD-1 monoclonal antibody, has demonstrated clinical benefit for patients with NSCLC. The underlying response and resistance mechanisms to tislelizumab treatment remain unknown. Methods Baseline tumor samples from 59 nonsquamous (NSQ) and 41 squamous (SQ) NSCLC patients treated with tislelizumab monotherapy (NCT02407990 and NCT04068519) were tested for gene mutations using large panel next generation sequencing and RNA expression using gene expression profiling (GEP; Precision Immuno-Oncology Panel, HTG Molecular Diagnostics). GEP analyses of NSQ and SQ NSCLC were performed separately due to different gene expression patterns. Results The ORR, mPFS, and mOS in this pooled NSCLC cohort were 15.2% (95% CI: 9.0, 23.6), 4.1 months (95% CI: 2.20, 6.11), and 15.1 months (95% CI: 11.20, NE), respectively, with a median study follow-up of 15.3 months (95% CI: 14.06, 15.90). Non-responders (NRs) exhibited distinct tumor and immune gene signature profiles and could be clustered into two subgroups: NR1 and NR2. Compared with responders, NR1 had elevated cell cycle signatures in both NSQ (P=0.2) and SQ (P=0.03) cohorts, and a trend of decreased inflamed gene signature profiles. However, NR2 showed comparable or even higher tumor inflammation (18-gene), and CD8+ T-cell signature scores in both NSQ and SQ cohorts and could be classified as immune hot. To explore the resistance mechanisms of immune hot NRs, differentially expressed gene analyses between immune hot NR2 and responders were performed. M2 macrophage and Treg signature scores were higher in NR2 in both NSQ (M2, P=0.05; Treg, P=0.03) and SQ (M2, P=0.05 [subgroup of NR2]; Treg, P=0.03) cohorts; significantly higher expression of immune regulatory genes included PIK3CD, CCR2, CD244, IRAK3, and MAP4K1 (P<0.05) in NSQ and PIK3CD, CCR2, CD40, CD163, and MMP12 (P<0.05) in SQ. Significantly higher epithelial–mesenchymal transition (EMT) and angiogenesis gene expression, including SNAI1, FA

Published
2020

228. 389P Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%

Author

Wu, Y-L., primary, Zhang, L., additional, Fan, Y., additional, Zhou, J., additional, Zhou, Q., additional, Li, W., additional, Hu, C., additional, Chen, G., additional, Zhang, X., additional, Zhou, C., additional, Souza, F., additional, Lin, J., additional, Wang, J., additional, Li, B., additional, and Mok, T., additional

Published
2020
Full Text
View/download PDF

230. 383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping

Author

Yang, J.C-H., primary, Le, X., additional, Cho, B.C., additional, Han, J-Y., additional, Morise, M., additional, Chen, Y-M., additional, Kang, J-H., additional, Kato, T., additional, Takeoka, H., additional, Chikamori, K., additional, Sakai, H., additional, Park, K., additional, Wu, Y-L., additional, Schumacher, K., additional, Bruns, R., additional, Straub, J., additional, and Paik, P., additional

Published
2020
Full Text
View/download PDF

232. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

Author

Tsuboi, M., primary, Wu, Y-L., additional, He, J., additional, John, T., additional, Grohe, C., additional, Majem, M., additional, Goldman, J.W., additional, Laktionov, K., additional, Kim, S-W., additional, Kato, T., additional, Vu, H.V., additional, Akewanlop, C., additional, Yu, C-J., additional, de Marinis, F., additional, Domine, M., additional, Shepherd, F.A., additional, Yan, C., additional, Atasoy, A., additional, and Herbst, R., additional

Published
2020
Full Text
View/download PDF

241. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Author

Chen, G., Feng, J., Zhou, C., Wu, Y.-L., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C.-P., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., and You, C.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results